Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. However, the guidance ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential ... so on that basis, the stock is very inexpensive. The GLP-1 market continues ...

Eli Lilly (LLY) stock dips despite strong weight-loss drug sales as the company's Q1 2025 results fall short of forecasts. Read more here.

Eli Lilly & Co has experienced a significant stock price drop of 10.58% over the past week, despite delivering impressive first-quarter results for 2025. The company’s revenue s ...

Eli Lilly's Q1 numbers showed strong revenue and earnings growth, driven by its GLP-1 offerings. The company's 2025 outlook disappointed investors, however, leading to the decline. The stock ...